Foli Bio was founded with the mission of transforming gut health through non-invasive transcriptomic profiling and molecular diagnostics. We are a fast-growing company actively building collaborations and partnerships to bring precision tools to the clinic and pharmaceutical industry.
Foli-seq™ is Foli Bio's proprietary exfoliated RNA profiling technology that captures host transcriptomic signals from shed gut epithelial and immune cells in stool, providing a non-invasive snapshot of mucosal biology. With high sensitivity and reproducibility, Foli-seq™ enables a wide range of molecular readouts, including immune activation, epithelial barrier integrity, pathway-level activity, and more.
Built on the Foli-seq™ technology, our platform analyzes rare human RNA from stool to generate high-dimensional transcriptomic data. Combined with advanced AI/ML-driven analytics, it supports a wide range of applications in precision medicine and drug development, including biomarker identification, patient stratification, therapeutic response prediction and novel druggable target discovery. The platform is designed to support both clinical and translational research through non-invasive, data-rich insights into gut biology.
Leveraging our Foli-seq™ platform, Foli Bio is advancing clinical and translational programs to drive precision diagnostics, targeted therapy selection, and data-driven drug development for gastrointestinal diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and colorectal cancer (CRC), through collaborations and partnerships with top academic institutions and leading pharmaceutical companies.
Foli Bio is actively collaborating with preeminent academic institutes and top-5 pharmaceutical companies to unlock a new dimension of gut-derived insights through our Foli-seq™ platform. We welcome new partners seeking to advance precision diagnostics, biomarker discovery, and data-driven drug development.
